A peptide-mediated targeting gene delivery system for malignant glioma cells

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3631-3640

  Wang, Chuanwei ^a,b   Ning, Liping ^c   Wang, Hongwei ^a,b   Lu, Zaijun ^b   Li, Xingang ^a,b   Fan, Xiaoyong ^d   Wang, Xuping ^a   Liu, Yuguang ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Drug delivery systems; Gene transfer techniques; Glioblastoma; Nanoparticles; Polyethylenimine

Indexed keywords

NANOPARTICLE; POLYETHYLENEIMINE; POLYETHYLENEIMINE VALYLTHREONYLTRYPTOPHYLTHREONYLPROLYLGLUTAMYLALANYLTRYPTOPHYLGLUTAMYLTRYPTOPHYLVALINE NANOPARTICLE; POLYMER; POLYPEPTIDE; UNCLASSIFIED DRUG; VALYLTHREONYLTRYPTOPHYLTHREONYLPROLYLGLUTAMYLALANYLTRYPTOPHYLGLUTAMYLTRYPTOPHYLVALINE;

ANIMAL CELL; ARTICLE; CANCER PROGNOSIS; CONJUGATION; CONTROLLED STUDY; CYTOPLASM; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE TARGETING; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; INTERNALIZATION; NONHUMAN; PEPTIDE SYNTHESIS; RAT;

DRUG-DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GLIOBLASTOMA; NANOPARTICLES; POLYETHYLENIMINE;

ANIMALS; CELL LINE, TUMOR; DNA; GENE TARGETING; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; NANOCAPSULES; PEPTIDES; RATS; TRANSFECTION;

EID: 84884559924     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S44990     Document Type: Article

References (38)

1. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemi-ology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2006;20(4):E1.
2. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro Oncol. 2001;3(3):141-151.
3. Das P, Puri T, Jha P, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci. 2010;18(1):66-70.
4. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci. 2010;17(4): 417-421.
5. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resec-tion, and survival. J Neurosurg. 2001;95(2):190-198.
6. Kew Y, Levin VA. Advances in gene therapy and immunotherapy for brain tumors. Curr Opin Neurol. 2003;16(6):665-670.
7. Germano IM, Binello E. Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol. 2009;93(1): 79-87.
8. Yawata T, Maeda Y, Okiku M, Ishida E, Ikenaka K, Shimizu K. Identification and functional characterization of glioma-specific pro-moters and their application in suicide gene therapy. J Neurooncol. 2011;104(2):497-507.
9. Guo DS, Wang BF, Han FX, Lei T. RNA interference therapy for glioblastoma. Expert Opin Biol Ther. 2010;10(6):927-936.
10. Mathupala SP, Guthikonda M, Sloan AE. RNAi based approaches to the treatment of malignant glioma. Technol Cancer Res Treat. 2006;5(3):261-269.
11. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24-25):3477-3496.
12. Park JS, Na K, Woo DG, et al. Non-viral gene delivery of DNA poly-plexed with nanoparticles transfected into human mesenchymal stem cells. Biomaterials. 2010;31(1):124-132.
13. Luten J, van Nostruin CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release. 2008;126(2):97-110.
14. van Gaal EVB, van Eijk R, Oosting RS, et al. How to screen non-viral gene delivery systems in vitro? J Control Release. 2011;154(3):218-232.
15. Boussif O, Lezoualch F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92(16):7297-7301.
16. Lungwitz U, Breunig M, Blunk T, Gopferich A. Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm. 2005;60(2): 247-266.
17. Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7(5):657-663.
18. Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther. 2000;7(2):262-268.
19. Li D, Ping YA, Xu FJ, et al. Construction of a star-shaped copolymer as a vector for FGF receptor-mediated gene delivery in vitro and in vivo. Biomacromolecules. 2010;11(9):2221-2229.
20. Kuo YC, Liang CT. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor. Biomaterials. 2011;32(12):3340-3350.
21. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science. 1990;249(4967):386-390.
22. Wu CX, Lo SL, Boulaire J, et al. A peptide-based carrier for intracel-lular delivery of proteins into malignant glial cells in vitro. J Control Release. 2008;130(2):140-145.
23. Brewer GJ, Torricelli JR. Isolation and culture of adult neurons and neurospheres. Nat Protoc. 2007;2(6):1490-1498.
24. Snyder SL, Sobocinski PZ. An improved 2,4,6-trinitrobenzenesul-fonic acid method for the determination of amines. Anal Biochem. 1975;64(1):284-288.
25. Nair HB, Sung B, Yadav VR, Kannappan R, Chaturvedi MM, Aggarwal BB. Delivery of antiinflammatory nutraceuticals by nanopar-ticles for the prevention and treatment of cancer. Biochem Pharmacol. 2010;80(12):1833-1843.
26. Tzeng SY, Guerrero-Cazares H, Martinez EE, Sunshine JC, Quinones-Hinojosa A, Green JJ. Non-viral gene delivery nanopar-ticles based on poly(beta-amino esters) for treatment of glioblastoma. Biomaterials. 2011;32(23):5402-5410.
27. Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted syn-thetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 2006;3(1):e6.
28. Castro MG, Candolfi M, Kroeger K, et al. Gene therapy and targeted toxins for glioma. Curr Gene Ther. 2011;11(3):155-180.
29. Candiani G, Pezzoli D, Ciani L, Chiesa R, Ristori S. Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PLoS One. 2010;5(10):e13430.
30. Safdar S, Taite LJ. Targeted diazeniumdiolates: localized nitric oxide release from glioma-specific peptides and proteins. Int J Pharm. 2011;422(1-2):264-270.
31. Troiber C, Wagner E. Nucleic acid carriers based on precise polymer conjugates. Bioconjug Chem. 2011;22(9):1737-1752.
32. Barbet J, Machy P, Leserman LD. Monoclonal antibody covalently coupled to liposomes: specific targeting to cells. J Supramol Struct Cell Biochem. 1981;16(3):243-258.
33. Orlandi R, Canevari S, Leoni F, Mezzanzanica D, Ripamonti M, Colnaghi MI. Change in binding reactivity of an anti-tumor mono-clonal antibody after the introduction of 2-pyridyl disulphide groups. Hybridoma. 1986;5(1):1-8.
34. Berthold PR, Shiraishi T, Nielsen PE. Cellular delivery and antisense effects of peptide nucleic acid conjugated to polyethyleneimine via disulfide linkers. Bioconjug Chem. 2010;21(10):1933-1938.
35. Chang JY. Structural heterogeneity of 6 M GdmCl-denatured proteins: implications for the mechanism of protein folding. Biochemistry. 2009;48(40):9340-9346.
36. Lateef SS, Gupta S, Jayathilaka LP, Krishnanchettiar S, Huang JS, Lee BS. An improved protocol for coupling synthetic peptides to car-rier proteins for antibody production using DMF to solubilize peptides. J Biomol Tech. 2007;18(3):173-176.
37. Roseman M, Jencks WP. Interactions of urea and other polar compounds in water. J Am Chem Soc. 1975;97(3):631-640.
38. Grigsby CL, Leong KW. Balancing protection and release of DNA: tools to address a bottleneck of non-viral gene delivery. J R Soc Interface. 2010;7 Suppl 1:S67-S82.